Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Ferrer Advances Research on Progressive Supranuclear Palsy with Phase II
Details : FNP-223 is a small molecule oral tablet, which is being evaluated in the mid-stage clinical trial studies to slow the progression of Progressive Supranuclear Palsy.
Brand Name : FNP-223
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 17, 2024
Ferrer Advances Research into PSP with the Inclusion of the First Participant in a Trial
Details : FNP-223 is an orally administered small molecule drug candidate, which is currently being evaluated for the treatment of progressive supranuclear palsy.
Brand Name : FNP-223
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2024
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Recipient : United Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Ferrer Obtains the Distribution Rights of a Potential Treatment for IPF and PPF
Details : The agreement aims for the distribution of Tyvaso (treprostinil inhalation solution), a drug-device combination authorized for the treatment of WHO Group 3 PH-ILD.
Brand Name : Tyvaso
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 27, 2024
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Recipient : United Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : VRG50635
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Verge Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Verge Genomics Partners with Ferrer To Co-Develop ALS Therapy VRG50635
Details : The collaboration aims to co-develop VRG50635, Verge’s potent PIKfyve inhibitor, for treating sporadic & familial amyotrophic lateral sclerosis in various regions, including Europe & Southeast Asia.
Brand Name : VRG50635
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 25, 2024
Lead Product(s) : VRG50635
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Verge Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Ferrer Reports Top-Line Results from Phase III ADORE Study in ALS
Details : FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Brand Name : FNP 122
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2024
Ferrer Extends their Clinical Study in Amyotrophic Lateral Sclerosis (ALS)
Details : FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Brand Name : FNP 122
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2023
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Asceneuron
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.
Brand Name : ASN90
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Asceneuron
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Aspirin,Ramipril,Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : CNIC
Deal Size : Not Applicable
Deal Type : Not Applicable
The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction
Details : The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.
Brand Name : Polypill
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 26, 2022
Lead Product(s) : Aspirin,Ramipril,Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : CNIC
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : United Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Ferrer has been appointed as the exclusive, worldwide distributor to commercialise Tyvaso (treprostinil) for the treatment of PH-ILD, a rare, serious and progressive disease without an approved treatment in Europe and many other part...
Brand Name : Tyvaso
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 28, 2022
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : United Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : FNP122 as an oral formulation of edaravone in ALS patients. Edaravone is an antioxidant and free radical scavenger that has been shown to reduce excess oxidative stress and cell death1, playing an important role in the pathology of ALS.
Brand Name : FNP122
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2021
LOOKING FOR A SUPPLIER?
Reset All
